Published in Clin Auton Res on April 01, 1992
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
'The clocks that time us'--circadian rhythms in neurodegenerative disorders. Nat Rev Neurol (2014) 1.20
Circadian and sleep disorders in Parkinson's disease. Exp Neurol (2012) 1.03
Twenty-four hour non-invasive ambulatory blood pressure and heart rate monitoring in Parkinson's disease. Front Neurol (2013) 0.96
Cardiovascular assessment of falls in older people. Clin Interv Aging (2006) 0.91
Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. J Neurol (2014) 0.85
Nondipping in Parkinson's disease. Parkinsons Dis (2011) 0.83
Blood pressure fluctuation and hypertension in patients with Parkinson's disease. Brain Behav (2013) 0.78
Evaluation of Cardiac Autonomic Functions in Older Parkinson's Disease Patients: a Cross-Sectional Study. Aging Dis (2016) 0.78
Diurnal blood pressure and urine production in acute spinal cord injury compared with controls. Spinal Cord (2016) 0.76
Consequences of Circadian Disruption on Neurologic Health. Sleep Med Clin (2015) 0.75
Neurocardiovascular Instability and Cognition. Yale J Biol Med (2016) 0.75
Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension. Drugs Real World Outcomes (2015) 0.75
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna) (2017) 0.75
Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. Clin Auton Res (2015) 0.75
Central hemodynamics and arterial stiffness in idiopathic and multiple system atrophy. J Neurol (2016) 0.75
Prescription of drugs during pregnancy in France. Lancet (2000) 4.12
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf (2006) 1.96
[Late myopathies located at the spinal muscles: a cause of acquired lumbar kyphosis in adults]. Rev Rhum Mal Osteoartic (1991) 1.59
Renal artery stent placement: long-term results with the Wallstent endoprosthesis. Radiology (1994) 1.43
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
Water drinking and the heart. Lancet (1999) 1.34
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33
Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens (2001) 1.29
Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int (2000) 1.27
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol (2002) 1.27
Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol (1985) 1.26
Sleep attacks and Parkinson's disease treatment. Lancet (2000) 1.25
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain (1997) 1.23
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. Rev Neurol (Paris) (1982) 1.18
Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol (1989) 1.15
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol (1992) 1.13
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain (1989) 1.09
Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci (1992) 1.09
[Carpal tunnel syndrome, amyloid tenosynovitis and periodic hemodialysis]. Rev Neurol (Paris) (1981) 1.08
Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol (2009) 1.08
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol (2007) 1.07
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology (2002) 1.07
Yohimbine increases human salivary secretion. Br J Clin Pharmacol (1989) 1.07
Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther (1994) 1.04
The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther (1992) 1.03
Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol (1997) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord (2001) 1.01
User procedure for self-measurement of blood pressure. First International Consensus Conference on Self Blood Pressure Measurement. Blood Press Monit (2000) 1.01
Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry (1991) 1.01
Odorous urine in man after asparagus. Br J Clin Pharmacol (1989) 1.00
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging (2001) 0.99
Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol (1991) 0.99
[Drug-induced hiccup: a review of the France pharmacologic vigilance database]. Therapie (1999) 0.99
Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab (2008) 0.98
Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007) 0.97
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry (1994) 0.97
[Drug vigilance: opinion survey among residents of a university hospital]. Therapie (1995) 0.96
Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. J Clin Pharm Ther (2013) 0.94
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol (1999) 0.94
"Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol (2005) 0.94
[Subcortical aphasia. Neruolinguistic and x-ray computed tomography studies of 25 cases]. Rev Neurol (Paris) (1984) 0.93
Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction (2004) 0.92
Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin (2007) 0.91
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm (Vienna) (2003) 0.91
Alpha-adrenolytic properties of bromocriptine in dogs. Arch Int Pharmacodyn Ther (1982) 0.91
Pure motor hemiplegia: CT study of 30 cases. Stroke (1982) 0.91
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord (1994) 0.91
[Cerebral hemodynamics and clinical pharmacology in Parkinson disease]. Therapie (1988) 0.90
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine (2011) 0.90
[Effect of bromocriptine on cerebral blood flow in Parkinson's disease]. Rev Neurol (Paris) (1988) 0.90
Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf (2000) 0.90
[Drug-induced alopecia: review of the literature]. Therapie (1995) 0.90
Focal cerebral hypoperfusion and selective cognitive deficit in dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry (1987) 0.90
Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res (1991) 0.90
Apomorphine test in parkinsonian syndromes. Lancet (1990) 0.90
A study of salivary secretion in Parkinson's disease. Clin Neuropharmacol (1999) 0.90
Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs. Eur J Pharmacol (1987) 0.89
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol (1996) 0.88
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol (2008) 0.88
Yohimbine increases salivary secretion in depressed patients treated with tricyclic antidepressants. Eur J Clin Pharmacol (1990) 0.88
The pharmacologic treatment of gait ignition failure. Adv Neurol (2001) 0.88
Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res (1992) 0.87
Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol (2004) 0.87
Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry (1979) 0.87
A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry (1992) 0.87
[Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution]. Therapie (2001) 0.87
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol (2004) 0.87
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry (1994) 0.87
A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol (2001) 0.86
Differential regulation of fat cell beta-2 and beta-1 adrenoceptors by endogenous catecholamines in dog. J Pharmacol Exp Ther (1989) 0.86
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol (1991) 0.86
Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol (1995) 0.86
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet (1993) 0.86
2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey. Vaccine (2010) 0.85
Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis (2007) 0.85
Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol (2006) 0.85